Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia - Patients to Be Treated with RP-L102 under “Process B” Incorporating Higher Cell Doses, ...
RP-L201 has received FDA Regenerative Medicine Advanced Therapy (RMAT), Rare Pediatric, Fast Track and Orphan Drug designations; Rocket eligible for Priority Review Voucher, if RP-L201 is approved ...
Rocket Pharmaceuticals has withdrawn its application seeking Food and Drug Administration approval of its RP-L102 proposed gene therapy for the treatment of the rare, inherited blood disorder Fanconi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback